Effects of modified obestatin fragment (FNAPEP-NH2) on body weight gain, food and water consumption, and changes in pain thresholdстатья

Статья опубликована в высокорейтинговом журнале
Статья опубликована в журнале из списка Web of Science и/или Scopus

Работа с статьей

[1] Effects of modified obestatin fragment (fnapep-nh2) on body weight gain, food and water consumption, and changes in pain threshold / E. Motorykina, E. E. Khirazova, M. V. Maslova et al. // European Neuropsychopharmacology. — 2016. — Vol. 26. According to World Health Organization overweight and obesity are major risk factors for a number of chronic diseases. That is why it is highly important to fight obesity on any level possible, and especially effective can be usage of endogenous anorectic peptides. Obestatin is a peptide that is encoded by the same gene with ghrelin, they are both postranslationally cleaved from their precursor – preproghrelin. It has been initially shown that obestatin decreases body weight, food and water consumption [1]. Even though obestatin itself attracts a lot of attention as potential anorectic peptide, its smaller fragments could be more perspective in changing body weight. However, there is quiet few information exist about obestatin fragments [2]. Our research group has previously demonstrated, the obestatin fragment 1–4 (FNAP-NH2) decreased body weight in adult male rats, but to achieve any practical use, this effect should be prolong and enhance. Beside excessive weight another common problem for obese people is general and specific musculoskeletal pain, along with abdominal pain, chronic widespread pain and some other kinds of pain. That is why anorectic substance that also affects pain pathways would be in great demand. Considering all these data, we found it essential to investigate the effect of obestatin modified fragment (FNAPEP-NH2) on weight gain, food and water consumption and changes in pain threshold in adult male Wistar rats. To prolong and enhance the effect of FNAP-NH2 we used several modifications, the most effective of which was FNAPEP-NH2. As for the initial fragment the strongest effect was observed after 5 days of intranasal injection, we decided to stick with this scheme of experiment. For five days during the research animals received intranasal one of different doses of obestatin fragment FNAPEP-NH2: 0.1, 1, 10, 300 or 1000 nmol/kg. Control animals were injected same amount of saline. A week before and during whole experiment adult rats were housed individually and were fed ad libitum, at that period of time body mass, food, and water intake were registered daily. To evaluate the level of pain threshold Tail Flick test was used on the next day and a week after the injection. As a result, we discovered, that the most efficient dose on FNAPEP-NH2 was 10 nmol/kg, as chronical injection of this dose lead to significant decrease in body weight (from 13 to 17 app to 10.5% p < 0.05 M-W). Food consumption was also decreased (12–15 days, max – 58% p < 0.05 M-W), the same for water consumption (15–16 days, max – 53% p < 0.05 M-W). Pain threshold was increased on the next day (app to 53% p < 0.05 M-W) and in a week of last injection (app to 51% p < 0.05 M-W). This data demonstrate, that modified obestatin fragment FNAPEP-NH2 possessed strong anorectic effect on body weight gain and food and water consumption, in the same time pain threshold was significally increased. This effect can be potentially useful; however additional studies to discover the mechanism of this process are highly required.

Публикация в формате сохранить в файл сохранить в файл сохранить в файл сохранить в файл сохранить в файл сохранить в файл скрыть